Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert D'Haens

Showing results (131-140 of 269) with videos related to

Pageof 27
Sort By:
Gut|January 7, 2011
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialWalter Reinisch, William J Sandborn, Daniel W Hommes, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2010
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximabWilliam J Sandborn, Maria T Abreu, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|September 20, 2022
Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn's DiseaseVincent Joustra, Joris van Sabben, Eline van der Does de Willebois, et al.
Inflammatory Bowel Diseases|May 4, 2019
Capsule Retention in Crohn's Disease: A Meta-analysisShabana F Pasha, Marco Pennazio, Emanuele Rondonotti, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 11, 2006
Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trialStefan Schreiber, Brian Feagan, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|May 15, 2026
Hyperbaric oxygen therapy alters bowel perfusion and improves outcomes in patients with treatment-refractory ulcerative colitis: a prospective pilot trialLieven Mulders, Maarten Pruijt, Joep Van Oostrom, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 28, 2017
Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome SetChristopher Ma, Remo Panaccione, Richard N Fedorak, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 24, 2025
Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD StudyBruce E Sands, Stefan Schreiber, Marla C Dubinsky, et al.
Journal of Crohn'S & Colitis|March 27, 2026
Timing matters: recommendations for outcome assessment in real-world evidence studies of Crohn's diseasePaula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 9, 2024
Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced TherapiesBruce E Sands, Geert D'Haens, Remo Panaccione, et al.
Pageof 27

Showing results (131-140 of 269) with videos related to

Sort By:
Pageof 27
Gut|January 7, 2011
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialWalter Reinisch, William J Sandborn, Daniel W Hommes, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2010
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximabWilliam J Sandborn, Maria T Abreu, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|September 20, 2022
Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn's DiseaseVincent Joustra, Joris van Sabben, Eline van der Does de Willebois, et al.
Inflammatory Bowel Diseases|May 4, 2019
Capsule Retention in Crohn's Disease: A Meta-analysisShabana F Pasha, Marco Pennazio, Emanuele Rondonotti, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 11, 2006
Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trialStefan Schreiber, Brian Feagan, Geert D'Haens, et al.
Journal of Crohn'S & Colitis|May 15, 2026
Hyperbaric oxygen therapy alters bowel perfusion and improves outcomes in patients with treatment-refractory ulcerative colitis: a prospective pilot trialLieven Mulders, Maarten Pruijt, Joep Van Oostrom, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 28, 2017
Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome SetChristopher Ma, Remo Panaccione, Richard N Fedorak, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 24, 2025
Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD StudyBruce E Sands, Stefan Schreiber, Marla C Dubinsky, et al.
Journal of Crohn'S & Colitis|March 27, 2026
Timing matters: recommendations for outcome assessment in real-world evidence studies of Crohn's diseasePaula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 9, 2024
Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced TherapiesBruce E Sands, Geert D'Haens, Remo Panaccione, et al.
Pageof 27